menu
    • menu

    Company profile for Skyhawk Therapeutics

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    Smithfield BioScience transforms bioproducts into trusted, life-saving therapies through safe, reliable U.S.-based manufacturing.

    Virtual Booth

    Contact Supplier

    Quotient Sciences- Molecule to Cure. Fast.

    Virtual Booth

    Contact Supplier

    SWATI - Transforming science into solutions with 60+ years of expertise, global accreditations, and pioneering biotech innovation.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    REF. STANDARDS & IMPURITIES

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    At Skyhawk Therapeutics we use proprietary structural, kinetic, and computational models to invent small molecules that correct splicing in RNA, targeting some of the world's most intractable diseases. Our mission is to revolutionize disease treatment by developing small molecule therapeutics that correct RNA expression

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Skyhawk TherapeuticsUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    35 Gatehouse Drive Waltham, MA 02451
    Telephone
    Telephone
    617.858.0041 ​ ​
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://skyhawktx.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/skyhawk-therapeutics/
    youtube
    YouTube
    Twitter
    Twitter
    https://x.com/skyhawk_tx?lang=en

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    DDL Conference

    Not Confirmed

    envelop Contact Supplier

    DDL Conference

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Skyhawk Therapeutics Reports Positive Phase 1 Results
    Skyhawk Therapeutics Reports Positive Phase 1 Results

    17 Sep 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/skyhawk-therapeutics-announces-positive-first-interim-results-in-patients-from-its-phase-1-clinical-trial-of-sky-0515-as-a-treatment-for-huntingtons-disease-302559083.html

    PR NEWSWIRE
    17 Sep 2025
    Share Share
    Merck KGaA Partner with Skyhawk in $2B RNA Splicing Collaboration
    Merck KGaA Partner with Skyhawk in $2B RNA Splicing Collaboration

    19 Aug 2025

    // PRESS RELEASE

    https://www.skyhawktx.com/post/skyhawk-therapeutics-announces-strategic-collaboration-with-merck-kgaa-darmstadt-germany-to-discov

    PRESS RELEASE
    19 Aug 2025
    Share Share
    Skyhawk: First Patient Dosed in Phase 2/3 FALCON-HD Trial
    Skyhawk: First Patient Dosed in Phase 2/3 FALCON-HD Trial

    17 Jun 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/skyhawk-therapeutics-announces-first-patient-dosed-in-phase-23-falcon-hd-trial-of-sky-0515-for-huntingtons-disease-302483907.html

    PR NEWSWIRE
    17 Jun 2025
    Share Share
    Skyhawk Receives Australian Approval to SKY-0515 in Huntington
    Skyhawk Receives Australian Approval to SKY-0515 in Huntington

    09 Dec 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/skyhawk-therapeutics-receives-australian-regulatory-approval-to-extend-sky-0515-treatment-duration-in-phase-1-huntingtons-disease-patient-trial-302326386.html

    PR NEWSWIRE
    09 Dec 2024
    Share Share
    Skyhawk Presents SKY-1214 Data At EORTC-NCI-AACR Symposium
    Skyhawk Presents SKY-1214 Data At EORTC-NCI-AACR Symposium

    24 Oct 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/skyhawk-therapeutics-presents-compelling-preclinical-data-on-sky-1214-at-the-eortc-nci-aacr-molecular-targets-and-cancer-therapeutics-symposium-302285986.html

    PR NEWSWIRE
    24 Oct 2024
    Share Share
    Skyhawk To Present SKY-0515 Phase 1 Data At Huntington's Disease Network
    Skyhawk To Present SKY-0515 Phase 1 Data At Huntington's Disease Network

    11 Sep 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/skyhawk-therapeutics-to-present-additional-positive-topline-data-from-parts-a-and-b-of-phase-1-clinical-trial-of-sky-0515-at-european-huntingtons-disease-network-and-enroll-hd-2024-302244451.html

    PR NEWSWIRE
    11 Sep 2024
    Share Share

    REF. STANDARDS & IMPURITIES

    Upload your portfolio for free, ask us

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search